September 5th, 2014
Perspectives on PARADIGM-HF
CardioExchange Editors, Staff
The Editors present a distillation of reader comments on a popular post.
September 1st, 2014
Let’s Take a Close Look at PARADIGM-HF
Vinay Prasad, MD MPH
Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.
August 30th, 2014
Will There Be a PARADIGM Shift in Treatment of Heart Failure?
John McMurray, MbChB MD and Milton Packer, MD
John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.
October 22nd, 2012
Selections from Richard Lehman’s Literature Review: October 22nd
Richard Lehman, BM, BCh, MRCGP
This week’s topics include favorable lipid-level trends in U.S. adults, an angiotensin receptor neprilysin inhibitor for patients with HF and preserved systolic ejection fraction, and a long-term safety comparison of the Zotarolimus-eluting and Sirolimus-eluting coronary stents.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?